| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Clinical Pharmacy and Psychiatry, Obstetrics and Gynecology, Psychiatry, and Biostatistics and Epidemiology, University of Tennessee, Memphis, Tennessee
Abstract
Objective: To determine whether depot leuprolide is effective in premenstrual syndrome (PMS) and whether symptom type or severity affects therapeutic or hormonal responses and the incidence of adverse events.
Methods: Twenty-five women who met strict diagnostic criteria for FMS completed a double-blind, placebo-controlled, 6-month crossover trial at a university medical center. Depot leuprolide (3.75 mg/month) or saline was administered intramuscularly for three consecutive treatment cycles. Efficacy, adverse events, and hormone concentrations were assessed at each visit. Repeated-measures analysis of variance was used to analyze continuous data, and ordinal and binary data were analyzed using nonparametric techniques.
Results: Depot leuprolide treatment was significantly more effective than placebo on all rating scales. Irritability, neurologic symptoms, breast tenderness, and fatigue were most responsive to treatment. Symptoms were reduced to follicular phase levels only in women without premenstrual depression. Those with moderate premenstrual depression improved but remained clinically symptomatic, whereas the group with severe premenstrual depression showed no improvement on any efficacy measure. Adverse events were lowest in those without premenstrual depression and highest in those with severe depression. Leuprolide suppressed estradiol and progesterone in most premenstrual depression groups but had varying effects on gonadotropins.
Conclusions: Leuprolide treatment reduced both behavioral and physical symptoms and was well tolerated in the absence of severe premenstrual depression. Women should be evaluated for depression severity before receiving a GnRH agonist. The differential response to leuprolide suggests that it may possess diagnostic value in determining distinct subtypes of PMS.
This article has been cited by other articles:
|
|
 |
|
  C. I Jarvis, A. M Lynch, and A. K Morin Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder Ann. Pharmacother., July 1, 2008; 42(7): 967 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Thys-Jacobs, D. McMahon, and J. P. Bilezikian Differences in Free Estradiol and Sex Hormone-Binding Globulin in Women with and without Premenstrual Dysphoric Disorder J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Yonkers, C. Brown, T. B. Pearlstein, M. Foegh, C. Sampson-Landers, and A. Rapkin Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder Obstet. Gynecol., September 1, 2005; 106(3): 492 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Grady-Weliky Premenstrual Dysphoric Disorder N. Engl. J. Med., January 30, 2003; 348(5): 433 - 438. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Schmidt, L. K. Nieman, M. A. Danaceau, L. F. Adams, and D. R. Rubinow Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome N. Engl. J. Med., January 22, 1998; 338(4): 209 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rubinow and P. J. Schmidt The Treatment of Premenstrual Syndrome -- Forward into the Past N. Engl. J. Med., June 8, 1995; 332(23): 1574 - 1575. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
